NASDAQ:FRLN Freeline Therapeutics (FRLN) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free FRLN Stock Alerts $6.48 0.00 (0.00%) (As of 02/20/2024) Add Compare Share Share Today's Range$6.48▼$6.4850-Day Range$6.39▼$6.4952-Week Range$2.11▼$8.74VolumeN/AAverage Volume12,055 shsMarket Capitalization$28.12 millionP/E RatioN/ADividend YieldN/APrice Target$11.13 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Freeline Therapeutics alerts: Email Address Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About Freeline Therapeutics Stock (NASDAQ:FRLN)Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.Read More FRLN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FRLN Stock News HeadlinesFebruary 25, 2024 | benzinga.comFreeline Therapeutics Stock (NASDAQ:FRLN) Dividends: History, Yield and DatesFebruary 20, 2024 | finance.yahoo.comAcquisition of Freeline by Syncona Becomes EffectiveMarch 29, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.February 20, 2024 | globenewswire.comAcquisition of Freeline by Syncona Becomes EffectiveFebruary 13, 2024 | finanznachrichten.deFreeline Therapeutics Shareholders Approve Acquisition by SynconaFebruary 12, 2024 | finance.yahoo.comFreeline Shareholders Approve Acquisition by SynconaFebruary 9, 2024 | uk.finance.yahoo.comFreeline Therapeutics Holdings plc (FRLN)December 1, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SRC, EAR, PATI, FRLNMarch 29, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.November 30, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Argenx Se (ARGX) and Freeline Therapeutics Holdings (FRLN)November 29, 2023 | businesswire.comFREELINE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Freeline ...November 23, 2023 | finance.yahoo.comFreeline (FRLN) Shares Rise on Merger Agreement With SynconaNovember 22, 2023 | finanznachrichten.deSyncona Limited to Acquire Freeline TherapeuticsNovember 22, 2023 | tmcnet.comFRLN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Freeline Therapeutics Holdings plc Is Fair to ShareholdersNovember 18, 2023 | seekingalpha.comFRLN Freeline Therapeutics Holdings plcNovember 5, 2023 | morningstar.comFreeline Therapeutics Holdings PLC ADR FRLNOctober 28, 2023 | markets.businessinsider.comFreeline Therapeutics: Promising Initial Efficacy Data and Potential for High Revenues Justify Buy RatingOctober 25, 2023 | finance.yahoo.comFreeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual CongressOctober 19, 2023 | finance.yahoo.comHere's Why We're A Bit Worried About Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn SituationOctober 18, 2023 | markets.businessinsider.comWhere Freeline Therapeutics Stands With AnalystsOctober 16, 2023 | finance.yahoo.comFreeline to Present New Clinical Data for FLT201 in Gaucher Disease in Oral Presentation at Upcoming ESGCT 30th Annual CongressOctober 6, 2023 | marketwatch.comFreeline Therapeutics ADRs Rise 14% Following Positive Trial Data on FLT201October 5, 2023 | markets.businessinsider.comPromising Gaucher Disease Trial Results and Potential Parkinson’s Disease Impact Bolster Analyst’s Buy Rating for Freeline Therapeutics HoldingsOctober 4, 2023 | benzinga.comWhy Is Gene Therapy Player Freeline Therapeutics Stock Trading Higher Today?October 4, 2023 | markets.businessinsider.comFreeline Reports Positive Data From First Cohort Of Phase 1/2 GALILEO-1 Trial Of FLT201October 4, 2023 | finance.yahoo.comFreeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher DiseaseAugust 17, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Buy Rating for Freeline Therapeutics Holdings (FRLN)See More Headlines Receive FRLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Freeline Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today3/29/2024Next Earnings (Estimated)4/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:FRLN CUSIPN/A CIK1810031 Webwww.freeline.life Phone44-0-14-3890-6870FaxN/AEmployees152Year FoundedN/APrice Target and Rating Average Stock Price Target$11.13 High Stock Price Target$30.00 Low Stock Price Target$3.00 Potential Upside/Downside+71.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($5.5939) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-88,970,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-150.46% Return on Assets-97.01% Debt Debt-to-Equity RatioN/A Current Ratio1.95 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$12.07 per share Price / Book0.54Miscellaneous Outstanding Shares4,340,000Free Float4,259,000Market Cap$28.12 million OptionableNot Optionable Beta0.66 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Michael J. Parini J.D. (Age 49)CEO & Executive Director Comp: $2.16MMr. Paul M. Schneider (Age 53)CFO & Director Dr. Henning R. Stennicke Ph.D. (Age 56)Chief Scientific Officer Ms. Nicole Jones SPHR (Age 53)Chief People Officer Mr. James Bircher (Age 56)Chief Technical Operations Officer Dr. Pamela Foulds M.D. (Age 54)Chief Medical Officer Ms. Naomi AokiSenior Vice President of Corporate Communications & Investor RelationsMs. Amy J. Spandau (Age 49)Interim Head of Finance More ExecutivesKey CompetitorsAileron TherapeuticsNASDAQ:ALRNUnity BiotechnologyNASDAQ:UBXLianBioNASDAQ:LIANSynlogicNASDAQ:SYBXTRACON PharmaceuticalsNASDAQ:TCONView All CompetitorsInstitutional OwnershipBlue Owl Capital Holdings LPBought 86,654 shares on 2/15/2024Ownership: 1.996%Sphera Funds Management LTD.Bought 16,445 shares on 2/15/2024Ownership: 0.379%PenderFund Capital Management Ltd.Bought 60,401 shares on 2/14/2024Ownership: 1.391%UBS Group AGBought 65,154 shares on 2/9/2024Ownership: 2.289%Harbor Capital Advisors Inc.Bought 7,848 shares on 1/8/2024Ownership: 0.469%View All Institutional Transactions FRLN Stock Analysis - Frequently Asked Questions Should I buy or sell Freeline Therapeutics stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Freeline Therapeutics in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" FRLN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FRLN, but not buy additional shares or sell existing shares. View FRLN analyst ratings or view top-rated stocks. What is Freeline Therapeutics' stock price target for 2024? 3 analysts have issued 12-month price targets for Freeline Therapeutics' shares. Their FRLN share price targets range from $3.00 to $30.00. On average, they predict the company's share price to reach $11.13 in the next twelve months. This suggests a possible upside of 71.7% from the stock's current price. View analysts price targets for FRLN or view top-rated stocks among Wall Street analysts. How have FRLN shares performed in 2024? Freeline Therapeutics' stock was trading at $6.37 at the beginning of the year. Since then, FRLN stock has increased by 1.7% and is now trading at $6.48. View the best growth stocks for 2024 here. When is Freeline Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 2nd 2024. View our FRLN earnings forecast. How were Freeline Therapeutics' earnings last quarter? Freeline Therapeutics Holdings plc (NASDAQ:FRLN) posted its quarterly earnings results on Tuesday, November, 9th. The company reported ($12.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($15.20) by $2.30. When did Freeline Therapeutics' stock split? Freeline Therapeutics's stock reverse split on Friday, May 12th 2023. The 1-15 reverse split was announced on Friday, May 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Freeline Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Freeline Therapeutics investors own include Adobe (ADBE), BigCommerce (BIGC), Checkmate Pharmaceuticals (CMPI), CVS Health (CVS), Old Dominion Freight Line (ODFL), Oak Street Health (OSH), Rocket Companies (RKT), Shopify (SHOP), Zoom Video Communications (ZM) and Zymeworks (ZYME). When did Freeline Therapeutics IPO? Freeline Therapeutics (FRLN) raised $126 million in an initial public offering on Friday, August 7th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Morgan Stanley and Evercore ISI acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Freeline Therapeutics' major shareholders? Freeline Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include UBS Group AG (2.29%), Blue Owl Capital Holdings LP (2.00%), PenderFund Capital Management Ltd. (1.39%), Harbor Capital Advisors Inc. (0.47%) and Sphera Funds Management LTD. (0.38%). How do I buy shares of Freeline Therapeutics? Shares of FRLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FRLN) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyMost important medical advance in 100 yearsThe Oxford ClubBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Freeline Therapeutics Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.